TKNO (Alpha Teknova Inc) שולי הרווח הגולמי

Alpha Teknova, Inc. (TKNO) creates unique environments in collaboration with gene therapy developers, advancing a pragmatic R&D pipeline of custom reagents. The supply of critical vaccine buffers ensures a stable cash flow and high profitability. The gross margin trend on the GURU.Markets chart clearly demonstrates cost efficiency, where 33.90 characterizes this specific parameter for assessing current solvency.
פילוחי מדדים פיננסיים ומדדי שוק עבור Teknova Inc (TKNO)

Gross margin measures the profit share after deducting direct production costs, reflecting the efficiency of cost management for Alpha Teknova, Inc. (TKNO) chemical reagents. By analyzing the gross profit ratio, an investor assesses the company's ability to pass costs onto consumers, which, combined with recurring biopharmaceutical demand, confirms the issuer's exceptional financial stability and cash flow predictability.